Quest Diagnostics Inc (DGX)
適正価値ファンダメンタル
73
株価
$231.91
時価総額
$26.23B
パート1 · 企業の価値
概要
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 2026年9月18日 with claude-haiku-4-5 — shared with all users
Labcorp is the other national US clinical laboratory network, selling the same routine and specialty test menu to the same physicians, hospitals, health plans and employers, and competing directly for the same managed-care contracts and hospital outreach deals.
Through Sonic Healthcare USA it runs a large network of regional clinical laboratories serving American physicians and hospitals, the same customers Quest bids for, and it is also Quest's main rival in Canada after the LifeLabs acquisition.
As one of the largest US reference laboratories, it takes in specialty and esoteric testing sent out by hospitals and physician practices across the country, the higher-value volume Quest's advanced diagnostics business targets.
A non-profit national reference laboratory owned by the University of Utah that competes for the same hospital and health-system send-out testing contracts Quest pursues with its hospital lab services.
It sells oncology and molecular testing to US pathologists, oncologists and hospitals, overlapping with the cancer and genetic testing line Quest is expanding within its advanced diagnostics.
Its clinical diagnostics division runs routine and specialty testing laboratories, including in the United States, competing for the same physician and hospital testing volumes as Quest.
貸借対照表と流動性
売上高
$11.56B
直近12か月（2026/6/30まで）
純利益
$1.06B
直近12か月（2026/6/30まで）
フリーキャッシュフロー
$1.36B
自己資本合計
$7.17B
負債合計
$9.02B
流動比率
1.59
利払い倍率
6.37
負債/EBITDA
3.00
一株当たり利益（EPS）
売上高と純利益
フリーキャッシュフロー
収益内訳
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$222.23
現在株価
$231.91
安全マージン
-4.4%
適正価値レンジ
$155.33 - $289.13
使用した評価手法間のばらつきであり、統計的に較正された信頼区間ではありません。
推定方法
バリュエーション指標
P/E レシオ
24.74
ROE
13.8%
P/B レシオ
3.42
P/FCF
19.07
粗利益率
33.1%
ROIC
8.5%
収益性レーダー
価値創造（経済的モート）
ROIC
8.5%
WACC
7.1%
ROIC − WACC
+1.4 pp
ROICが資本コストを上回っています。企業は株主のために価値を創出しています。
ファンダメンタル分析基準
合格（20）
- EPS shows upward trend
- EPS CAGR 9.39%
- Price CAGR 9.85%
- ROIC 8.5%
- Gross Margin 33.1%
- P/FCF 19.07
- Debt/Equity ratio
- Operating Margin 14.1%
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 14.5%
- Analyst Consensus 57% Buy
- Earnings Surprise avg 4.8%
- Earnings Quality (OCF/NI) 1.79
- Share Dilution 0.1%
- Net Margin Trend 9.2% vs 9.0%
- Piotroski F-Score 8/9
不合格（6）
- P/B Ratio 3.42
- CapEx intensity
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Revenue Growth 5Y 3.2%
データなし（2）
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-スコア
財務健全性が高い
利益の質
高品質：利益はキャッシュに裏付けられている
株式希薄化
株式数は安定している
機関投資家の保有
ガバナンス
経営陣
| 氏名 | 役職 | 年齢 |
|---|---|---|
| Mr. James E. Davis | Chairman, CEO & President | 62 |
| Mr. Sam A. Samad | Executive VP & CFO | 55 |
| Mr. Michael E. Prevoznik J.D. | Senior VP & General Counsel | 63 |
| Ms. Catherine T. Doherty | Executive Vice President of Regional Businesses | 62 |
| Mr. Karthik Kuppusamy Ph.D. | Senior Vice President of Clinical Solutions | 55 |
| Mr. Michael J. Deppe | Senior VP, Corporate Controller & Chief Accounting Officer | 58 |
| Mr. Murali Balakumar | Senior VP and Chief Information & Digital Officer | - |
| Ms. Damini Chokshi | Vice President of Investor Relations | - |
| Ms. Kristin Lee Wallace Esq. | Senior VP & Chief Compliance Officer | - |
| Mr. Garry Clark | Senior VP and Chief Marketing & Communications Officer | - |
監査リスク
6
取締役会リスク
7
報酬リスク
2
株主権利リスク
2
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容：テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
業績推移
via SEC EDGAR
Latest News
Recent headlines for DGX, sourced from Markets Gazette.